Distributing Is Not Licensing: PDL BioPharma Loses Patent, Royalty Battle With MedImmune
This article was originally published in The Pink Sheet Daily
Executive Summary
A California federal court rules that a PDL patent claim is invalid and that MedImmune did not have to pay royalties on sales by its ex-U.S. distributor Abbott; MedImmune may seek repayment of $280 million in royalties.